■使用各种抗癌药物的经导管动脉化疗栓塞(TACE)通常用于治疗肝细胞癌(HCC)。我们的目的是比较TACE与抗癌药物与经导管动脉栓塞(TAE)治疗HCC的疗效和副作用。
■HCC患者被随机分为TACE或TAE组。每位患者治疗多达五个目标结节。Lipiodol(Lp;10mL),造影剂(CM;10mL),表柔比星(40毫克),丝裂霉素C(10毫克),米铂(70毫克),TACE组注射1-2-mm2天可溶性明胶海绵颗粒(2D-SGS),而Lp(10mL),CM(10mL),TAE组注射2D-SGS。对目标结节的治疗效果(TE)进行分级(TE1-TE4),并评估患者的反应。治疗后三个月,进行血液检查以比较肿瘤标志物和不良事件.
■纳入54例患者和161个目标结节;28例患者中的75个结节接受了TACE治疗,26例患者中86个结节接受TAE治疗。TE1,TE2,TE3和TE4分级的结节数量分别为1,28,7和39,分别在TACE组和2、25、7和52组中,在TAE组中。TACE和TAE组的有效率分别为89%(25/28)和73%(19/26)。分别。TE没有显著差异,反应率,或两组之间的血液检查结果。
■在肝癌的肝动脉栓塞治疗中,抗癌药物在栓塞后3个月对疗效或副作用没有任何影响。
UNASSIGNED: Transcatheter arterial chemoembolization (TACE) using various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC). We aimed to compare the therapeutic efficacy and side effects of TACE with anticancer drugs versus transcatheter arterial embolization (TAE) without anticancer drugs for HCC.
UNASSIGNED: Patients with HCC were randomized to either the TACE or TAE group. Up to five target nodules were treated in each patient. Lipiodol (Lp; 10 mL), contrast media (CM; 10 mL), epirubicin (40 mg), mitomycin C (10 mg), miliplatin (70 mg), and 1-2-mm 2-day soluble gelatin sponge particles (2D-SGS) were injected into the TACE group, whereas Lp (10 mL), CM (10 mL), and 2D-SGS were injected into the TAE group. Treatment effect (TE) of the target nodules was graded (TE1-TE4) and patient responses were assessed. Three months after treatment, blood tests were performed to compare tumor markers and adverse events.
UNASSIGNED: Fifty-four patients and 161 target nodules were included; 75 nodules in 28 patients were treated by TACE, and 86 nodules in 26 patients were treated by TAE. The number of nodules graded TE1, TE2, TE3, and TE4 was 1, 28, 7, and 39, respectively, in the TACE group and 2, 25, 7, and 52, respectively, in the TAE group. The response rates were 89% (25/28) and 73% (19/26) in the TACE and TAE groups, respectively. There were no significant differences in TE, response rates, or blood test results between the two groups.
UNASSIGNED: In hepatic arterial embolization for HCC, anticancer drugs did not have any impact on the therapeutic efficacy or side effects at 3 months after embolization.